BIOLQ Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -89.35%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -79.98%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 18418.52%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 141.48%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.838%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.2M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$2M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 8.18x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 2.92%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -34.78%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 18418.52%. On the other hand Envista Holdings has an analysts' consensus of $19.04 which suggests that it could grow by 3.21%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.5%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $616.9M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $18M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 1.27x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of -13.16% compared to Biolase's net margin of 6.62%. Biolase's return on equity of -21668.17% beat Solventum's return on equity of 11.75%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 18418.52%. On the other hand Solventum has an analysts' consensus of $82.17 which suggests that it could grow by 11.34%. Given that Biolase has higher upside potential than Solventum, analysts believe Biolase is more attractive than Solventum.

Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Solventum quarterly revenues of $2.1B. Biolase's net income of -$1.4M is lower than Solventum's net income of $137M. Notably, Biolase's price-to-earnings ratio is -- while Solventum's PE ratio is 34.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 1.55x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of 2.28%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -35.57%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 18418.52%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 16.08%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.215%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.1% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $879M. Biolase's net income of -$1.4M is lower than Dentsply Sirona's net income of $20M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.01x versus 0.85x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.